Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B7
Source: 0001140361-25-000634
Chunk: 13

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B7
Chunk 13
---
 any prospectus relating to offers and sales of any such preferred stock forms a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This description will include:

| • | the title and stated value; |

| • | the number of shares offered; |

| • | the liquidation preference per share; |

| • | the purchase price per share; |

| • | the dividend rate(s), period(s) and/or payment date(s) or method(s) of calculation for dividends; |

| • | whether dividends are cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; |

| • | our right, if any, to defer payment of dividends and the maximum length of such deferral period; |

| • | the procedures for auction and remarketing, if any; |

| • | the provisions for a sinking fund, if any; |

| • | the provision for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; |

| • | any listing of the preferred stock on any securities exchange or market; |

| • | the terms and conditions, if applicable, upon which the preferred stock will be convertible into Common Stock, including the conversion price (or manner of calculation) and conversion period; |

| • | whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or how it will be calculated, and the exchange period; |

| • | voting rights, if any, of the preferred stock; |

| • | preemptive rights, if any; |

| • | restrictions on transfer, sale or other assignment, if any; |

| • | whether interests in the preferred stock will be represented by depositary shares; |

| • | a discussion of any material and/or special U.S. federal income tax considerations applicable to the preferred stock; |

| • | the relative ranking and preferences of the preferred stock as to dividend rights and rights upon the liquidation, dissolution or winding up of our affairs; |

| • | any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the class or series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of our affairs; and |

| • | any other specific terms, preferences